Clinical Trial Update: A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC [Phase 2]

View source ↗

Summary

Phase 2 study evaluating a triple combination of Ociperlimab, Tislelizumab, and BAT1706 in advanced hepatocellular carcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• BAT1706 (BAT1706)
• Ociperlimab (ociperlimab)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: BeiGene | Conditions: Advanced Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2025-02-24